NCT01912963View on ClinicalTrials.gov

Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
HER2-positive Breast CancerMetastatic Breast Cancer
Interventions
DRUG

Pertuzumab

DRUG

Trastuzumab

DRUG

eribulin

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Eisai Inc.

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER